Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future
Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.
Overview
In May 2023, Johnson & Johnson (NYSE: JNJ) finalized the spin-off of its healthcare division, now called Kenvue. The decision to do so was largely motivated by management's desire to focus the company's efforts toward advancing its pharmaceutical segment. Narrowing its focus to pharmaceuticals and medical technology products has seemed like the right call. As of this writing, Johnson & Johnson's share price is up 55.5% over the past year compared to the S&P 500's 20.7% return.
That strong stock price performance is tied to momentum related to strong performances from some of its newer drugs, optimism about recent FDA approvals and clearances, and an improved outlook. It's likely to continue, as J&J management recently offered an 11-word phrase during its 2026 second-quarter earnings call that hinted at bullish news in the year ahead.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.